Exchange: NASDAQ·Updated 07:34 PM EDT
GDRX logo

GDRXGoodRx Holdings Inc

$2.93
$0.12
(3.82%)
Today
Closed $3.02
$0.0886
(2.93%)
After Hours
EarningsAug 5
Mkt Cap$1.06B
Vol879,744.00
News
all
press releases
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call
GoodRx Holdings, Inc. (Nasdaq: GDRX) (GoodRx or the Company), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference...
Business Wire
More News
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?
GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
GDRX or HQY: Which Is the Better Value Stock Right Now?
GDRX vs. HQY: Which Stock Is the Better Value Option?
Zacks
Is GoodRx (GDRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
GoodRx Holdings, Inc. (GDRX) Strengthens Recurring Revenue Base with Companion
GoodRx Holdings, Inc. (GDRX) Strengthens Recurring Revenue Base with Companion...
Yahoo! Finance: News
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one...
Business Wire
Hims & Hers Deepens Personalized Care Through Platform Expansion
HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.
Zacks
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OPRX cuts 2026 revenue view to $95-$100M as MFN pricing disruption and macro uncertainty squeeze budgets - will pressures ease?
Zacks
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.
Zacks
<
1
2
...
>

Advertisement|Remove ads.